Skip to main content
. Author manuscript; available in PMC: 2013 Apr 14.
Published in final edited form as: Leukemia. 2011 Nov 25;26(6):1356–1364. doi: 10.1038/leu.2011.340

Figure 6.

Figure 6

Differential effects of LBH on pSTAT3-positive versus pSTAT3-negative DLBCL survival: (a–e) pSTAT3-positive DLBCL lines Ly3, HBL1 and U2932 (a–c) and pSTAT3-negative DLBCL lines DHL6, Ly1 and Ly19 (d–f) were treated with various concentrations of LBH for 48 h and survival was assessed by flow cytometry. Data represent the mean±s.d. of three independent experiments. (g, h) pSTAT3 + (Ly3) and pSTAT3− (DHL6) cells were treated with various concentrations of LBH and lysates were probed for PARP (g) and acetylated H3 and H4 (h) antibodies. (i, j) pSTAT3 + (Ly3) and pSTAT3− (DHL6) cells were treated with LBH for 24 h and lysates were probed with indicated antibodies.